ANALYTICAL CHEMISTRY AND STABILITY TESTING OF TREATMENT DRUGS Release Date: December 2, 1998 RFP AVAILABLE: N01DA-9-8093 P.T. National Institute on Drug Abuse The development of medications for the treatment of drug addiction is a major mission of the National Institute on Drug Abuse (NIDA). NIDA prepares potential treatment drugs for use in preclinical toxicology evaluation, pharmacological studies and clinical trials. The treatment drugs include both bulk drug substances (e.g., GBR-12909, tropane analogs, UH-232, cyclazocine, indanamines, etc.) and dosage forms (e.g., buprenorphine tablets, GBR-12909 capsules, cyclazocine capsules, etc.). These drugs are acquired by the Government from private industry, Government contractors/grantees or independent investigators. In order to assure the identity, strength, quality and purity of these materials, the Government has been performing quality control tests before using them in its research and development trials. NIDA is soliciting proposals from qualified organizations having the capacity to carry out the development of analytical methods, conduct quality control tests and dosage form preparation, and perform stability studies for compounds and dosage forms to be used in its medications development program. It is estimated that a three-year incrementally funded cost reimbursement (completion) type contract will be awarded with two one year options. RFP No. N01DA-9-8093 will be available electronically on or about December 7, 1998 and may be accessed through the Internet at the following address: http://www.nida.nih.gov/RFP/RFPList.html. Please note that the RFP for this acquisition will be streamlined to include only the Work Statement, Deliverables and Reporting Requirements, Special Requirements and Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. All information required for the submission of an offer will be contained in the electronic RFP package. Following proposal submission and the initial review process, offerors comprising the competitive range may be requested to provide additional documentation to the Contracting Officer. Responses to the RFP will be due on or about January 21, 1999. Any responsible offeror may submit a proposal that will be considered by the Government. This advertisement does not commit the Government to award a contract. INQUIRIES Inquiries may be direct to: Brenda O. Brooks Contracts Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 10-49 Rockville, MD 20857 Telephone: (301) 443-6677 FAX: (301) 443-7595 Email: bb76n@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |